Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Update

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) was the target of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 3,870,000 shares, a drop of 17.0% from the December 31st total of 4,660,000 shares. Based on an average daily volume of 1,690,000 shares, the days-to-cover ratio is presently 2.3 days.

Trevi Therapeutics Stock Down 3.3 %

TRVI stock traded down $0.14 during trading on Tuesday, hitting $4.08. 312,481 shares of the company's stock traded hands, compared to its average volume of 510,899. The business has a fifty day simple moving average of $3.72 and a two-hundred day simple moving average of $3.27. The firm has a market capitalization of $313.63 million, a P/E ratio of -9.27 and a beta of 0.88. Trevi Therapeutics has a 1 year low of $1.38 and a 1 year high of $4.68.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). During the same quarter last year, the firm posted ($0.08) earnings per share. On average, equities research analysts predict that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Trevi Therapeutics

Large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its position in shares of Trevi Therapeutics by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company's stock worth $40,000 after buying an additional 6,764 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in Trevi Therapeutics in the second quarter valued at approximately $61,000. Intech Investment Management LLC purchased a new position in Trevi Therapeutics in the third quarter worth $63,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Trevi Therapeutics during the fourth quarter worth $67,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Trevi Therapeutics by 87.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company's stock valued at $73,000 after purchasing an additional 11,450 shares during the last quarter. 95.76% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

TRVI has been the topic of a number of research analyst reports. Needham & Company LLC restated a "buy" rating and issued a $8.00 price target on shares of Trevi Therapeutics in a report on Thursday, December 12th. HC Wainwright upped their target price on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the stock a "buy" rating in a research note on Thursday, December 12th. B. Riley reaffirmed a "buy" rating and set a $6.00 price target on shares of Trevi Therapeutics in a research note on Monday, October 7th. Finally, D. Boral Capital reissued a "buy" rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, January 8th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Trevi Therapeutics has an average rating of "Buy" and a consensus price target of $9.31.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.